Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 659 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Mom Who Fought Breast Cancer While Pregnant Describes The Benefits Of... January 20, 2020 New targeted lung cancer screening programme on the horizon September 29, 2022 Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping... July 1, 2024 EMA Recommends Extension of Indications for Avelumab December 17, 2020 Load more HOT NEWS Physical Activity May Lessen the Effects of Chemobrain, Study Finds New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free Doing More—Together—to End Cancer as We Know It Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients...
